CTS-Clinical and Translational Science

Papers
(The H4-Index of CTS-Clinical and Translational Science is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Issue Information296
Evidence–time dilemma in a pandemic with high mortality: Can outcome‐driven decision making on vaccines prevent deaths?133
Pharmacokinetics of Sofosbuvir/Velpatasvir and efficacy of an alternate‐day treatment in hemodialysis patients with chronic hepatitis C infection97
Generalizability in real‐world trials64
A comprehensive Thai pharmacogenomics database (TPGxD‐1): Phenotype prediction and variants identification in 942 whole‐genome sequencing data60
Intradermal substance P as a challenge agent in healthy individuals56
Developing a clinical research infrastructure embedded in an academic medicine center that equitably supports future clinician scientists52
Gene polymorphism and prediction of toxicity to platinum‐based chemotherapy in patients with gynecologic cancer50
Risk factors for the development of sepsis in patients with cirrhosis in intensive care units44
Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications42
Expression of Concern:Zhou, Y., & Zhou, J.Tranilast Treatment Attenuates Cerebral Ischemia‐Reperfusion Injury in Rats Through the Inhibition of Inflammatory Responses Mediated by NF‐κB and 40
Issue Information39
First, Do No Harm: Addressing AI's Challenges With Out‐of‐Distribution Data in Medicine37
From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry37
Using partition analysis as a facile method to derive net clearances35
Lexicon for blood‐based early detection and screening: BLOODPAC consensus document34
Model‐informed assessment of ethnic sensitivity and dosage justification for Asian populations in the global clinical development and use of cladribine tablets33
ST2 and CSF‐1 as potential druggable targets of inflammatory bowel diseases: Results from two‐sample Mendelian randomization study33
Perspectives on Using Pharmacogenomics to Guide Tobacco Cessation: Survey Results From an American Indian Community32
Japanese Phase 1 Study for Global Development of Anti‐TL1A Antibody PF‐06480605: A Randomized, Placebo‐Controlled, Single‐Ascending Dose Study31
Nontraditional Factors Influencing Cardiovascular Disease Risk: Correlation Among Framingham Risk Score, Body Composition Index, and Sleep‐Breathing Monitoring Index30
In vitro safety “clinical trial” of the cardiac liability of drug polytherapy29
Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: A candidate gene approach28
The impact of skin color and tone on histamine iontophoresis and Doppler flowmetry measurements as a pharmacodynamic biomarker28
Pharmacogenomic landscape of Indian population using whole genomes26
Patient, industry, and regulatory perspective on antibody‐drug conjugates dose optimization26
0.39502811431885